1. Cummings JL. Dementia: the failing brain. Lancet, 1995; 345(8963): 1481-1489.

2. Cruts M, Hendriks L, Van Broeckhoven C. The presenilin genes: a new gene family involved in Alzheimer disease pathology. Hum Mol Genet 1996; 5: 1449-1455.

3. Bennett C, Crawford F, Osborne A, Diaz P, Hoyne J, Lopez R, Roques P, Duara R, Rossor M, Mullan M. Evidence that the APOE locus influences rate of disease progression in late onset familial Alzheimer's disease but is not causative. Am J Med Genet 1995; 60(1): 1-6.

4. Das HK, McPherson J, Bruns GAP, Karathanasis SK, Breslow JL. Isolation, characterization, and mapping to chromosome 19 of the human apolipoprotein E gene. J Biol Chem 1985; 260(10): 6240-6247.

5. Strittmatter WJ, Roses AD. Apolipoprotein E and Alzheimer disease. Proc Natl Acad Sci USA 1995; 92(11): 4725-4727.

6. Zannis VI, Just PW, Breslow JL. Human apolipo­protein E isoprotein subclasses are genetically determined. Am J Hum Genet 1981; 33(1): 11-24.

7. Boerwinkle E, Visvikis S, Welsh D, Steinmetz J, Hanash SM, Sing CF. The use of measured genotype in­formation in the analysis of quantitative phenotypes in man. II. The role of the apolipoprotein E polymorphism in determining levels, variability, and covariability of cho­lesterol, betalipoprotein, and triglycerides in a sample of unrelated individuals. Am J Med Genet 1989; 27(3): 567-582.

8. Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. Atherosclerosis 1988; 8(1): 1-21.

9. Breslow JL, Zannis VI, SanGiacomo TR, Third JL, Tracy T, Glueck CJ. Studies of familial type III hyperlipo­proteinemia using as a genetic marker the apoE phenotype E2/2. J Lipid Res 1982; 23(8): 1224-1235.

10. Mahley RW. Apolipoprotein E: Cholesterol trans­port protein with expanding role in cell biology. Science 1988; 240(4852): 622-628.

11. Takahashi S, Kawarabayasi Y, Nakai T, Sakai J, Yamamoto T. Rabbit very low density lipoprotein recep­tor: a low density lipoprotein receptor-like protein with distant ligand specificity. Proc Natl Acad Sci USA 1992; 89(19): 9252-9256.

12. Pitas RE, Boyles JK, Lee SH, Hui D, Weisgraber KH. Lipoproteins and their receptors in the central ner­vous system. Characterization of the lipoproteins in cere­brospinal fluid and identification of apolipoprotein B, E (LDL) receptors in the brain. J Biol Chem 1987; 262(29): 14352-14360.

13. Fagan, AM, Bu G, Sun Y, Daugherty A, Holtzman DM. Apolipoprotein E-containing high density lipoprotein promotes neurite outgrowth and is a ligand for the low density lipoprotein receptor-related protein. J Biol Chem 1996; 271(47): 30121-30125.

14. Nathan BP, Bellosta S, Sanan DA, Weisgraber KH, Mahley RW, Pitas RE. Differential effects of apoli­poprotein E3 and E4 on neuronal growth in vitro. Science 1994; 264(5160): 850-852.

15. St Clair D, Rennie M, Slorach E, Norrman J, Yates C, Carothers A. Apolipoprotein E epsilon-4 allele is a risk factor for familial and sporadic presenile Alzhei­mer's disease in both homozygote and heterozygote carri­ers. J Med Genet 1995; 32(32): 642-644.

16. Betard C, Robitaille Y, Gee M, Tiberghien D, Larrivee D, Roy P, Mortimer JA, Gauvreau D. Apo E allele frequencies in Alzheimer's disease, Lewy body de­mentia, Alzheimer's disease with cerebrovascular disease and vascular dementia. Neuroreport 1994; 5(15): 1893-1896.

17. Greenberg SM, Rebeck GW, Vonsattel JPG, Gomez-Isla T, Hyman BT. Apolipoprotein E epsilon-4 and cerebral hemorrhage associated with amyloid angiopathy. Ann Neurol 1995; 38(2): 254-259.

18. Amouyel P, Vidal O, Launay JM, Laplanche JL. The apolipoprotein E alleles as major susceptibility factors for Creutzfeldt-Jakob disease. Lancet 1994; 344(8933): 1315-1318.

19. Saunders AM, Strittmatter WJ, Schmechel D, St. George-Hyslop PH, Pericak-Vance MA, Joo SH, Rosi BL, Gusella JF, Crapper-MacLachlan DR, Alberts MJ, Hulette C, Crain B, Goldgaber D, Roses AD. Association of apoli­poprotein E allele E4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993; 43(8): 1467-1472.

20. Rebeck GW, Reiter JS, Strickland DK, Hyman PT. Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron 1993; 11(4): 575-580.

21. Poirier J, Davignon J, Bouthillier D, Kogan S, Bertrand P, Gauthier S. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet 1993; 342(8873): 697-699.

22. Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell PC, Jr. Rimmler JB, Locke PA, Conneally PM, Schmader KE, Small GW, Roses AD, Haines JL, Pericak-Vance MA. Protective effect of apoli­poprotein E type 2 allele for late onset Alzheimer disease. Nat Genet 1994; 7(2): 180-184.

23. Lahiri DK, Sambamurti K, Bennett DA. Apolipo­protein gene and its interaction with the environmentally driven risk factors: molecular, genetic and epidemiologi­cal studies of Alzheimer’s disease. Neurobiol Aging 2004; 25(5): 641-650. 

24. Mahley RW, Palaoglu EK, Atak Z, Dawson-Pepin J, Langlois AM, Cheung V, Onat H, Fulks P, Mahley LL, Vakar F, Ozbayrakci S, Gokdemir O, Winkler W. Turkish heart study: lipids, lipoproteins, and apolipoproteins. J Lipid Res 1995; 36(4): 839-859.

25. Malle E, Pfeiffer KP, Dugi K, Pfeiffer C, Glaum M, Oezcueruemez M, Kloer HU, Steinmetz A. Polymor­phisms of apolipoprotein A-IV and E in a Turkish popula­tion living in Germany. Hum Genet 1996; 98(3): 285-290.

26. Harmanci H, Emre M, Gurvit H, Bilgic B, Hanagasi H, Gurol E, Sahin H, Tinaz S. Risk factors for Alzheimer disease: a population-based case-control study in Istanbul, Turkey. J Alz Dis Assoc Dis 2003; 17(3): 139-145.

27. Yokes MB. Establishment of the methods used in the molecular analysis of Alzheimer’s disease in Turkey and the significance of ApoE genotyping in healthy and diseased individuals. MS Thesis, Bogazici University, Istanbul, Turkey, 1999.

28. Yokes MB, Gul O, Basak AN. A methodological comparison between RFLP analysis and the LightCycler technology – ApoE genotyping using the ApoE Mutation Detection Kit. Biochemica 2001; 4: 17-19.

29. Ewbank DC. Deaths attributable to Alzheimer's disease in the United States. Am J Pub Health 1999; 89(1): 90-92.

30. Sleegers K, Van Duijn CM. Alzheimer's disease: genes, pathogenesis and risk prediction. Commun Genet 2001; 4(4): 197-203.

31. Rice DP, Fox PJ, Max W, Segura E; The eco­nomic burden of Alzheimer’s disease care. Health Aff (Milwood) 1993; 12(2):164-176.

32. Ernst RL, Hay JW. The US economic and social cost of Alzheimer’s disease revisited. Am J Pub Health 1994; 84(8): 1261-1264.

33. Arno P, Levine C, Memmott MM. The economic value of informal caregiving. Health Aff (Milwood) 1999; 18(2): 182-188.

34. LaDu MJ, Pederson TM, Frail DB, Reardon CA, Getz GS, Falduto MT. Purification of apolipoprotein E attenuates isoform-specific binding to b-amyloid. J Biol Chem 1995; 270(16): 9030-9042.

35. Yang DS, Smith JD, Zhou Z, Gandy SE, Martins RN. Characterization of the binding of amyloid-b peptide to cell culture-derived native apolipoprotein e2, e3, and e4 isoforms and to isoforms from human plasma. J Neuro­chem 1997; 68(2): 721-725.

36. Gerdes LU, Klausen IC, Sihm I, Faergeman O. Apolipoprotein E polymorphism in a Danish population compared to findings in 45 other study populations around the world. Genet Epidemiol 1992; 9(3): 155-167.